Results 31 to 40 of about 1,127,554 (354)

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Arnold, Dirk, Brenner, Baruch, Galle, Peter R., Gockel, Ines, Klautke, Gunther, Lang, Hauke, Möhler, Markus, Roessler, Hans-Peter, Rödel, Claus, Schimanski, Carl Christoph, Schmidberger, Heinz, Thomaidis, Thomas, Trarbach, Tanja   +12 more
core   +1 more source

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Clinical Cancer Research, 2020
Purpose: While various studies have highlighted the prognostic significance of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional adjuvant therapy after pCR is not known.
Laura M. Spring, G. Fell, A. Arfè, C. Sharma, R. Greenup, K. Reynolds, Barbara L. Smith, B. Alexander, B. Moy, S. Isakoff, G. Parmigiani, L. Trippa, A. Bardia   +12 more
semanticscholar   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

Journal for ImmunoTherapy of Cancer, 2022
Background Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous cell carcinoma (ESCC); however, little is known about the efficacy of PD-1 blockade as neoadjuvant therapy in resectable ESCC.
Weixiong Yang, Xiangbin Xing, S. Yeung, Siyu Wang, Wenfang Chen, Y. Bao, Fang Wang, S. Feng, F. Peng, Xiaoyan Wang, Shuling Chen, M. He, Ningfang Zhang, Honglei Wang, B. Zeng, Zhenguo Liu, B. Kidane, C. Seder, K. Koyanagi, Y. Shargall, Honghe Luo, S. Peng, Chao Cheng   +22 more
semanticscholar   +1 more source

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

PLoS ONE, 2022
Background Diffuse malignant peritoneal mesothelioma (DMPM) is a rare variant of malignant mesothelioma, representing 10–15% of malignant mesothelioma cases.
Xiao Wang, Sharyn Katz, John Miura, Giorgos Karakousis, Leonid Roshkovan, Suzanne Walker, Sally McNulty, Christine Ciunci, Keith Cengel, Corey J. Langer, Melina E. Marmarelis   +10 more
doaj   +2 more sources

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Scientific Reports, 2022
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC).
Po-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, Yi-Lin Chen, Wan-Li Chen, Kuan-Yu Lin, Chung-Liang Ho, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Wu-Chou Su   +16 more
doaj   +1 more source

DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma : a preliminary report [PDF]

, 2018
Purpose: Neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) enables evaluation of the tumour neovasculature that occurs prior to any volume change, which
Fotedar, Vikas, Seam, Rajeev K., Sharma, Anjna, Sharma, Mukesh, Sharma, Sanjiv, Sood, Shikha   +5 more
core   +1 more source

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

JAMA Oncology, 2020
Importance Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed.
R. Nanda, Minetta C. Liu, C. Yau, R. Shatsky, L. Pusztai, A. Wallace, A. J. Chien, A. Forero-Torres, E. Ellis, Heather S. Han, A. Clark, K. Albain, J. Boughey, N. Jaskowiak, A. Elias, C. Isaacs, K. Kemmer, T. Helsten, M. Majure, E. Stringer-Reasor, C. Parker, Marie Catherine Lee, T. Haddad, R. Cohen, S. Asare, Amy Wilson, G. Hirst, R. Singhrao, K. Steeg, A. Asare, J. Matthews, S. Berry, A. Sanil, R. Schwab, W. Symmans, L. J. van ’t Veer, D. Yee, A. DeMichele, N. Hylton, M. Melisko, J. Perlmutter, H. Rugo, D. Berry, L. Esserman   +43 more
semanticscholar   +1 more source

Development and Validation of a Computed Tomography–Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

JAMA Network Open, 2021
Key Points Question Can computed tomography–based radiomics be used to predict patients’ response to neoadjuvant chemotherapy at diagnosis?
Wei Wang, Ying-Peng Peng, Xing-Yu Feng, Yan Zhao, Sharvesh Raj Seeruttun, Jun Zhang, Zixuan Cheng, Yong Li, Zaiyi Liu, Zhiwei Zhou   +9 more
semanticscholar   +1 more source

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art

Menopause Review, 2022
Ovarian cancer represents the fifth cause of cancer death among women, carrying one of the worst prognoses among gynaecological malignancies. The need to achieve no residual disease after surgery in order to optimize prognosis of advanced-stage ovarian ...
Chrysoula Margioula-Siarkou, Stamatios Petousis, Alexios Papanikolaou, Giuseppe Gullo, Georgia Margioula-Siarkou, Antonio Simone Laganà, Konstantinos Dinas, Frederic Guyon   +7 more
doaj   +1 more source